Bionano Genomics, which is developing the Saphyr system for next-generation genome mapping, filed on Thursday with the SEC to raise up to $35 million in an initial public offering.
The San Diego, CA-based company was founded in 2003 and booked $16 million in sales for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol BNGO. Roth Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
